Adjuvant-free peptide vaccine
CA 2490449 A1 · Owner: Diamond, Don J. · Inventors: Diamond, Don J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Linking the synthetically-derived T helper epitope PADRE, or one of several , tetanus TH epitopes to the immunodominant HLA A*0201-restricted CTL epitope from CMV-pp65 in a fusion peptide caused robust cytotoxic cellular immune responses in HLA A*0201/Kb transgenic mice. The fusion peptides are immunogenic when administered in saline solution by either subcutaneous or intranasal routes. CpG-containing single-stranded DNA (ss-ODN) when added to , the fusion peptides as an adjuvant dramatically upregulated immune , recognition by either route. Target cells which either expressed full length pp65 protein from vaccinia viruses or were sensitized with the CTL epitope encoded in the vaccine …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 25, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 25, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 25, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.